Objective: To compare surfactant administration via supraglottic airway device (SAD) vs. nasal CPAP alone or INSURE. Study design: A systematic search of PubMed, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials and Clinicaltrials.gov was performed. Articles meeting inclusion criteria (RCT, surfactant administration via SAD, laryngeal mask, I-gel) were assessed Results: Five RCTs were eligible. Surfactant administration via SAD reduced the need for intubation/mechanical ventilation (RR 0.57, 95%CI 0.38–0.85) and short-term oxygen requirements (MD −8.00, 95%CI −11.09 to −4.91) compared to nCPAP alone. Surfactant administration via SAD reduced the need for intubation/mechanical ventilation (RR 0.43, 95%CI 0.31–0.61), but increased short-term oxygen requirements (MD 3.10, 95%CI 0.51–5.69) compared to INSURE approach. Conclusions: In preterm infants with RDS, surfactant administration via SAD reduces the need for intubation/mechanical ventilation. Overall, available literature includes few, small, poor-quality studies. Surfactant administration via SAD should be limited to clinical trials. © 2018, Springer Nature America, Inc.

Calevo, M., Veronese, N., Cavallin, F., Paola, C., Micaglio, M., Trevisanuto, D. (2019). Supraglottic airway devices for surfactant treatment: systematic review and meta-analysis [10.1038/s41372-018-0281-x].

Supraglottic airway devices for surfactant treatment: systematic review and meta-analysis

Veronese, N.;
2019-01-01

Abstract

Objective: To compare surfactant administration via supraglottic airway device (SAD) vs. nasal CPAP alone or INSURE. Study design: A systematic search of PubMed, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials and Clinicaltrials.gov was performed. Articles meeting inclusion criteria (RCT, surfactant administration via SAD, laryngeal mask, I-gel) were assessed Results: Five RCTs were eligible. Surfactant administration via SAD reduced the need for intubation/mechanical ventilation (RR 0.57, 95%CI 0.38–0.85) and short-term oxygen requirements (MD −8.00, 95%CI −11.09 to −4.91) compared to nCPAP alone. Surfactant administration via SAD reduced the need for intubation/mechanical ventilation (RR 0.43, 95%CI 0.31–0.61), but increased short-term oxygen requirements (MD 3.10, 95%CI 0.51–5.69) compared to INSURE approach. Conclusions: In preterm infants with RDS, surfactant administration via SAD reduces the need for intubation/mechanical ventilation. Overall, available literature includes few, small, poor-quality studies. Surfactant administration via SAD should be limited to clinical trials. © 2018, Springer Nature America, Inc.
Calevo, M., Veronese, N., Cavallin, F., Paola, C., Micaglio, M., Trevisanuto, D. (2019). Supraglottic airway devices for surfactant treatment: systematic review and meta-analysis [10.1038/s41372-018-0281-x].
File in questo prodotto:
File Dimensione Formato  
s41372-018-0281-x.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 1.18 MB
Formato Adobe PDF
1.18 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/460103
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 11
social impact